False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma

Clinical Nuclear Medicine

Volumn 31, Issue 7, 2006, Pages 391-393

  Ford, Clyde D ^a   Gabor, Frank ^a   Morgan, Ross ^a   Dabbas, Bashar ^a  

^a LDS HOSPITAL   (United States)

Author keywords

PET scanning; Spleen

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LABORATORY DIAGNOSIS; MALE; NONHODGKIN LYMPHOMA; TUMOR NECROSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BURKITT LYMPHOMA; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DOXORUBICIN; ETOPOSIDE; FALSE POSITIVE REACTIONS; HUMANS; IFOSFAMIDE; LAPAROSCOPY; LYMPHOMA, B-CELL; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; REMISSION INDUCTION; SALVAGE THERAPY; SPLEEN; SPLENECTOMY; TOMOGRAPHY, X-RAY COMPUTED; UNNECESSARY PROCEDURES; VINCRISTINE;

EID: 33748126165     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000222952.30225.66     Document Type: Article

References (11)

1. Gurton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol. 2004;126:772.
2. Foo SS, Mitchell PL, Berlangieri SU, et al. Positron emission tomography scanning in the assessment of patients with lymphoma. Intern Med J. 2004;34:388.
3. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma. 2000;39:543.
4. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181.
5. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475.
6. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44:1072.
7. 18F-FDG PET/CT. J Nucl Med. 2005;46:52.
8. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925.
9. Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, et al. Accuracy of whole-body 18F-PET for restaging malignant lymphoma. Acct Med Austria. 2003;30:41.
10. Creameries U, Fairy U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055.
11. de Wit M, Bumann D, Beyer W, et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8(suppl 1):57.